The AMR Narrative

Fluoroquinolone-resistant Campylobacter species

Although great care has been taken in the compilation and preparation of all directory entries to ensure accuracy, we cannot accept responsibility for any errors or omissions. Any medical information is provided for education/information purposes only and is not designed to replace medical advice by a qualified medical professional. Please see our disclaimer at the bottom of this entry.

What are fluoroquinolone-resistant Campylobacter species?

Fluoroquinolone-resistant Campylobacter species are a type of Campylobacter species resistant to fluoroquinolones, antibiotics used to treat a lot of bacterial infections. Unfortunately, the high rates of resistance to fluoroquinolones have limited their usefulness in treating Campylobacter infections, as well.

What are Campylobacter species?

To understand fluoroquinolone-resistant Campylobacter species, it is important to know what Campylobacter species are.

Campylobacter are gram-negative bacteria. When observed under a microscope, they are corkscrew, rod-shaped, and typically tend to move. There are several species of Campylobacter, and Campylobacter jejuni is the most commonly implicated species in human infections.

Campylobacter species can cause gastroenteritis, but also life-threatening conditions in people with a weakened immune system (see Who is at risk of a Campylobacter infection).


Where can Campylobacter be found?

Campylobacter bacteria normally live in the intestines of many farm animals (including cattle, sheep, pigs, chickens, turkeys), and pets, such as cats and dogs. Therefore, the feces of these animals may contaminate water, milk, meat, and other foods.

How can Campylobacter spread?

It takes very few Campylobacter bacteria to make someone sick, and people may be infected in several ways:

• Drinking contaminated water. Indeed, water from lakes and streams can be contaminated by animal feces.
• Drinking unpasteurized raw milk or dairy products. Milk can be contaminated if a cow has a Campylobacter infection in her udder, or when milk is contaminated with manure. Pasteurization makes milk safe to drink.
• Eating raw or undercooked meat (usually poultry, but also other foods, such as seafood, and produce). Indeed, Campylobacter can be carried in the intestines, liver, and other organs of animals, and can be transferred to other parts when the animal is slaughtered.
• Eating food prepared on kitchen surfaces touched by contaminated meat.
• By contact with dog or cat feces.

Which infections can Campylobacter cause?

Campylobacter bacteriacan cause gastroenteritis. People with Campylobacter infection usually have diarrhoea (which may be watery, sometimes bloody), and abdominal pain, accompanied by fever, headache, nausea and vomiting. These symptoms usually start 2 to 5 days after the person ingests Campylobacter, and continue for about one week.

Most people completely recover within a week, but these bacteria can cause life-threatening infections in people with weakened immune systems (see Who is at risk of a Campylobacter infection). Indeed, microorganisms can occasionally spread inside the bloodstream (bacteremia), and infect other sites in the body, such as the joints (infectious arthritis).

Campylobacter infection rarely results in long-term health problems. However, peripheral nerves may be affected (polyneuropathy), causing the so-called Guillain-Barré syndrome, a medical condition with muscle weakness or sometimes paralysis that can last for weeks, and often requires intensive medical care.

Who is at risk of Campylobacter infections?

Anyone can develop a Campylobacter infection, but certain groups of people are at greater risk than others to develop serious conditions, including:

• infants and young children,
• adult aged 65 years or older,
• pregnant women,
• people with a weakened immune system, such as from HIV, immunosuppressants (medications which slow or stop the response of the immune system), or cancer chemotherapy.

How are Campylobacter infections diagnosed?

To correctly diagnose an infection caused by Campylobacter bacteria, first of all your physician will perform a physical examination and ask you about symptoms and risk factors. Guided by these elements, your doctor will be able to choose the most appropriate diagnostic tests.

Laboratory tests can identify Campylobacter using a sample taken from stool. These samples are sent to a laboratory to grow the microorganism over time using a media on a petri dish (culture) and identify it. Then susceptibility tests can be carried out to determine which antibiotics are most effective against it, to start the most appropriate antibiotic therapy.

Understanding which antibiotic will work best is especially key to fluoroquinolone-resistant Campylobacter species as these types of resistant Campylobacter bacteria may only respond to certain medicines.

Finally, depending on the severity of infection, your physician may recommend additional tests, such as imaging tests.

How are Campylobacter infections treated?

Most people recover from Campylobacter infection without antibiotic treatment. Patients have to drink extra fluids as long as diarrhea and vomiting last in order to avoid the risk of dehydration. However, people with, or at risk for, serious illness may need an antibiotic therapy.

The antibiotic may vary according to the results of susceptibility tests. Indeed, some infections, such as those ones caused by fluoroquinolone-resistant Campylobacter species, are resistant to this type of antibiotics.

Depending on the site and the severity of infection, the medication could be in the form of tablets to swallow. However, severe infections require to be treated in hospital with intravenous antibiotics (the medication is given through a drip or a tube), and additional therapies.

Due to the increasing resistance to the available antibiotics, Campylobacter infections are becoming more and more difficult to treat.

How can Campylobacter infections be prevented?

Following these precautions can lower your risk of getting a Campylobacter infection. Moreover, they help to reduce your chances of spreading bacteria to others, as well.

• Wash your hands thoroughly and regularly with soap and running water. Keeping your hands clean is particularly important before, during, and after preparing food; before eating food; after using the toilet; after changing diapers; after blowing your nose, coughing, or sneezing; before and after caring for someone who is sick; after touching pets and other animals or their food or stool; after touching garbage. Remember: hand hygiene is your best protection against infections.
• Keep raw poultry away from other foods. Use separate cutting boards for raw meat, and clean them properly. Clean all countertops, and utensils with soap and hot water after preparing any type of raw meat.
• Cook food to the right temperature. Be careful especially with poultry (chicken, turkey, duck, goose, and other farmed birds).
• Washing or scrubbing fruits and vegetables before eating.
• Only drink pasteurized milk.
• Do not drink untreated water.
• Take care with pets. Pets sometimes carry Campylobacter and other microorganisms that can make you sick.




Disclaimer: The information provided on this website is intended for educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Reliance on any information provided on this website is solely at your own risk. The website owners and authors are not responsible for any errors or omissions in the content or for any actions taken based on the information provided. It is recommended that you consult a qualified healthcare professional for individualised medical and health-related guidance.

Dr Marie-Anne Bouldouyre

Dr Marie-Anne Bouldouyre is an infectious diseases physician and hospital practitioner in Paris. Twelve years of clinical work in a suburban hospital shaped her understanding of access to care, patient relationships, and the daily reality of antimicrobial resistance.

Since 2022, she has led the Regional Antibiotic Stewardship Centre in Île-de-France and coordinates the national network, working with a multidisciplinary team to promote responsible antibiotic use and strengthen collaboration among healthcare professionals. She also continues to manage complex infections at Saint-Louis Hospital.

Convinced that antimicrobial resistance cannot be tackled by healthcare workers alone, she advocates for the active involvement of patients : understanding, questioning, and taking part in decisions about antibiotics. Their stories are essential to making this issue visible and concrete.

She is proud to collaborate with initiatives such as The AMR Narrative and hopes to foster similar projects in France to give patients a voice in this shared fight.

Dr Erva Cinar

Dr Erva Cinar is a London based paediatric resident doctor and clinical researcher with interest in infectious diseases.

She is currently completing a Master’s in Public Health at the London School of Hygiene & Tropical Medicine. Through the World Medical Association’s Junior Doctor’s Network (WMA-JDN) AMR Working Group, she engages in policy and advocacy on antimicrobial resistance and stewardship at global level.

Alongside her clinical and academic roles, she works with the Royal College of Paediatrics and Child Health (RCPCH) and the International Child Health Group (ICHG); leads on organising teaching resources and educational events to improve research skills for UK paediatric trainees and for global child health professionals.

Hamu Madzedze

Hamu Madzedze is a seasoned Zimbabwean journalist with over 15 years’ experience.

She previously worked for the Zimbabwe Broadcasting Corporation as a reporter and sub-editor, before establishing an independent website, 365HealthDiaries, which focuses on health and gender issues.

She holds a BA in Media Studies and a BA (Special Honours) in Communication and Media from the Zimbabwe Open University, as well as a diploma from the Christian College of Southern Africa.

Her work has been recognised with several awards, including the Global AMR Special Mention Award (2024), the Sexual Health Rights and Equity Fellowship Special Mention Award (2025), and the Merck Foundation Award (2024) for outstanding coverage of health issues, gender, infertility, and genital mutilation, where she achieved third position in the Online Category.

Hamu is passionate about addressing AMR through the media.

Jomana F. Musmar

Dr. Jomana Musmar is a distinguished global policy expert and proactive leader with over fifteen years of government experience in strategic planning, operational design, and policy execution. Renowned for simplifying complex topics with expertise and diplomacy, she has spearheaded innovative solutions to global health challenges, shaped impactful policies, and advanced national and international missions.

As the Executive Director of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, she established and led the council’s operations, liaising with over 600 experts, worldwide, across government, industry, and academia. Her efforts culminated in the development of critical recommendations addressing antimicrobial resistance and interrelated One Health issues, influencing both domestic and global health strategies.

In her tenure as Deputy Director of Strategic Initiatives for the Office of Infectious Diseases and HIV/AIDS Policy, at the US Department of Health and Human Services, Dr. Musmar oversaw the formulation and implementation of national health strategies for vaccines and a range of infectious diseases including HIV/AIDS and viral hepatitis. Her leadership and technical expertise facilitated groundbreaking policies during national emergencies, including responses to the COVID-19 pandemic, and initiatives to combat congenital syphilis and childhood vaccination disruptions. Dr. Musmar holds a Ph.D. in Biodefense from George Mason University, a Master’s degree in Biomedical Science policy and Advocacy from Georgetown University, and is a Lean Six Sigma Black Belt. Fluent in English and Arabic, she is a sought-after speaker and advisor, having represented the United States at premier global health conferences.

Her published works on antimicrobial resistance, pandemic preparedness, and national health security underscore her reputation as a thought leader and innovator in public health and biodefense.

Chris Shaffer

Chris Shaffer was a music, special education teacher, and high school principal for 45 years. At the end of his educational career, he was thrust into the world of AMR infections when a number of abdominal surgeries left him with an E-coli infection which failed to respond to antibiotics. After doctors in the USA left him with little hope for a cure, diminishing health, and a bleak prognosis, he set out on his own.

Chris found success in phage therapy at the Eliava Phage Therapy Center in Tbilisi, Georgia. With phage therapy giving Chris his life back, he has dedicated his retirement years to advocating for and helping raise awareness of phage therapy used for AMR infections. He tells the story of his phage journey in a book titled, Finding Phage: How I Partnered with a Friendly Virus to Cure My Deadly Bacterial Superinfection. His website, phagetherpyusa.com helps others learn to understand the healing power of phage therapy.

Demi Christofi

Demi is an Associate Scientific Director at a medical communications agency, with a background in microbiology and a longstanding focus on antimicrobial resistance. She holds an MSc in Microbiology, where she first became interested in the global challenge of resistance and the need to bring scientific understanding to wider audiences.

Demi’s career has centred on a simple but powerful belief: that how we communicate science matters. Her work focuses on making complex data clear, engaging, and accessible – whether for healthcare professionals, policy makers, or the patients most affected by infection and resistance. She has contributed to a wide range of AMR-focused projects, including educational programmes, congress communications and stewardship initiatives.

A central thread in Demi’s work is the importance of the patient voice. She is passionate about making sure real-world experiences of treatment failure, recurrent infections, and the anxiety surrounding resistance are not lost in the data. She believes that listening to patients and involving them meaningfully is essential for shaping more effective, human-centred responses to AMR.

Demi is also a strong advocate of the One Health approach, recognising AMR as a complex, interconnected issue that spans human health, animal health, and the environment. She is particularly drawn to efforts that move beyond siloed thinking and focus on practical, joined-up solutions.

In 2025, Demi joined The AMR Narrative as an Independent Advisor, where she supports the charity’s mission to centre communication, community, and inclusion in the global AMR response.

Outside of work, she is a Girlguiding unit leader and a qualified yoga teacher. These roles reflect her commitment to care, learning, and creating supportive spaces for others.

Andrea Hartley

Andrea has worked in health communications and campaigning for 3 decades. She is committed to fighting AMR through timely and appropriate communications globally,.

Andrea set up Skating Panda, the creative social and environmental impact consultancy, over a decade ago and drives its impact and growth. Focused on original and lasting public interest communications as well as issue strategy and advocacy, the Panda team has a track record of prompting tipping points in the status quo that drive better social and planetary outcomes.

Andrea’s combination of commercial marketing and development experience with deep issue knowledge have been sought by decision-makers at global summits, corporate and NGO board members, and have enabled her to set up multi-million fundraising platforms and push through policies that change and save lives. 

Andrea is Vice Chair of mothers2mothers, the world’s largest employer of women living with HIV, and a Board Director of Maymessy, a food poverty social enterprise.

A lifelong advocate for gender equality, she played a key role in establishing the UK’s Women’s Equality Party.

Esmita Charani

Professor Esmita Charani is a pharmacist and researcher investigating how we use antibiotics in different cultural and social contexts. She works with teams in the UK, India, and South Africa to develop research programmes investigating all aspects of antimicrobial resistance in human populations with a focus in hospital settings.

She has experience in communicating her research with patients and the public through various media including animations, blogs, and educational videos.